- For
- Metabolic health and longevity
- Form
- SubQ injection (5-10 mg)
- Dose
- 5-10 mg, 2-3x / week
- Cycle
- 4-8 weeks
- Safety
- Avoid with active cancer or pregnancy
- Legal
- Research peptide, not FDA-approved
Bottom line: A mitochondrial exercise-mimetic research peptide with real animal data and sparse human proof. Not a substitute for training.
Safety at a glance
- Status: Not FDA-approved; research peptide.
- Evidence: Mostly animal; human trials sparse.
- Do not use if: you have a cancer history - effects are experimental, with a theoretical tumor concern.
- Not medical advice - decide this with a licensed physician.
What it does - plain English
MOTS-c is a 16-amino-acid peptide (a tiny chain of protein building blocks) encoded by your mitochondrial DNA - the small genome inside your cellular power plants. Your mitochondria release it under metabolic stress: exercise, fasting, cold exposure. It signals to other cells: "we're under load, mobilize energy reserves."
Researchers got interested because mice given MOTS-c showed improved insulin sensitivity, reduced fat accumulation, and better exercise performance even on a high-fat diet. Insulin sensitivity means your cells respond to insulin the way they should - the opposite of what happens in type 2 diabetes.
The biohacker community calls it an "exercise mimetic" - a molecule that triggers some of exercise's metabolic benefits without the workout. That framing is partially true and partially oversold. More on that below.
What people use it for
A B-tier metabolic peptide. Where people aim it:
Status
B-tier / Watch. Animal evidence is genuinely interesting. The mechanism - mitochondrial-derived peptide signaling - is novel and well-documented in the research literature. That part is real science, not bro-science.
Human trials are sparse. Phase-1 safety data exists from CB4211, the pharmaceutical-grade version developed by CohBar, but Phase-2 efficacy results were mixed. CohBar wound down operations in 2023. The biohacker community runs ahead of the evidence base here - by a meaningful margin.
This is a "watch" entry. The mechanism is real. The human translation is unproven. Don't confuse "interesting science" with "proven therapy."
Legal status
MOTS-c is not FDA-approved for human use. It sits in the research-peptide gray zone. CB4211, the pharmaceutical-grade analog, is now owned by Lyra Therapeutics following CohBar's wind-down and is not commercially available to consumers.
What this means in practice: MOTS-c is sourced almost entirely through research peptide vendors who sell it legally as "for research use only, not for human consumption." There is no compounding pharmacy route the way there is for some other peptides - no doctor can write you a script for this one through a normal channel.
Where to source
Research peptide vendors with a COA (Certificate of Analysis - a third-party lab report verifying purity and dose) per batch. Always ask for a COA. No COA, no buy.
MOTS-c is one of the harder peptides to source well. Demand is low, synthesis is difficult, and vendor quality varies more than it does for higher-volume peptides like BPC-157. Two things to insist on:
- Lyophilized (freeze-dried) form - more stable than reconstituted. Reconstituted MOTS-c degrades faster, especially if shipping or storage conditions aren't ideal.
- Documented COA per batch, not per product line - you want the lab report for the specific lot you're buying, not a generic certificate attached to the product page.
Subscribe below to get vendor reviews and price snapshots in the weekly dispatch.
New to peptides? Start with the foundations ->
Two studies worth reading
The foundational mouse paper
Lee, C. et al., Cell Metabolism
The 2015 paper that put MOTS-c on the metabolic-research map. Mice on a high-fat diet given MOTS-c didn't gain weight or develop insulin resistance the way controls did. Sparked the whole "exercise mimetic" framing and anchored essentially every subsequent MOTS-c discussion.
Aging + exercise capacity
Reynolds, J. et al., Nature Communications
Aged mice receiving MOTS-c showed improved running performance and better muscle physiology. The paper that anchors the longevity-and-fitness use case and extends the story beyond pure metabolic health into age-related physical decline.
Last reviewed · 2026·05·04 · Status reviewed weekly